Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
  • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
  • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
  • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
  • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
  • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D207/36—Oxygen or sulfur atoms
  • C07D207/38—2-Pyrrolones
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/08—Antiepileptics; Anticonvulsants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/22—Anxiolytics

Definitions

• the invention relates to 1,5-dihydro-pyrrol-2-ones which contain a secondary amine radical in the 4-position and an aryl radical in the 1-position, processes for their preparation and their use as medicaments, especially for the treatment of Epilepsy of various forms and for the treatment of anxiety and tension
• Epilepsy is behavioral changes in the form of convulsions. The reason is short-term, extremely strong neuronal discharges of the brain. Overall, about 5% of all people experience an epileptic seizure in their life, 1% suffer from epilepsy
• the invention is therefore based on the object of providing compounds with favorable pharmacological properties which can be used as medicaments, in particular for the treatment of epilepsy.
• Sedation can negatively influence mental processes. In some cases, ataxia and coordination disorders can be observed, which affect performance.
• diazepam The most important representatives of the anxiolytics launched on the market are the active ingredients diazepam, clonazepam and medazepam.
• plasma concentrations 300 to 400 mg / ml are necessary.
• the side effects mentioned such as sedation and psychomotor disorders, also occur, which manifest themselves in day sedation, sleepiness, as well as limited attention and responsiveness.
• Due to the high half-life of diazepam and clonazepam there are strong "hang-over" effects, which are also associated with drowsiness, deterioration in intellectual and motor performance and longer reaction times.
• the anxiolytic effect of clonazepam is dependent on the sedative or hypnotic effect High doses of medazepam are also associated with hypnotic, muscle-relaxing effects.
• a further object of the present invention is therefore to provide medicaments for the treatment of different anxiety and tension states which have a wide therapeutic range.
• X hydrogen, halogen, -CC 4 alkyl, dC alkoxy, trifluoromethyl or trifluoromethoxy, nitro, amine;
• Y secondary amine, e.g. B. morpholine, piperidine, 2-
• Methylpiperidine, 3-methylpiperidine, 4-methylpiperidine, pyrrolidine, 4-methylpiperazine, azepam, diethylamino, bis (methoxyethyl) amine and; m 1 to 3 mean.
• Trifluoromethoxy, nitro, amine; m 1 to 3 mean.
• compounds of general formula 3 can be condensed with the corresponding amines.
• Trifluoromethoxy, nitro, amine; m 1 to 3 mean.
• the compounds according to the invention are suitable for the production of pharmaceutical compositions.
• the pharmaceutical compositions contain at least one of the compounds of the general formula 1.
• the medicaments can, for example, be administered parenterally (for example intravenously, intramuscularly subcutaneously) or orally.
• the application forms can be prepared by methods which are generally known and customary in pharmaceutical practice, customary pharmaceutical carriers and auxiliaries being used.
• the compounds according to the invention have strong pharmacological effects.
• the compounds of the invention were in vivo after i.p. -Application to mice or rats (po application) according to the international standard (Pharmac.Weekblad, Sc.Ed. 14, 132 (1992) and Antiepileptic Drugs, Third. Ed., Raven Press, New York 1989) on their anticonvulsant Effect tested (Table 1).
• the ED 5 o (po) was 19 mg / kg in the rat in maximum electroshock , in the pentetrazole cramp model the ED 5 o (po) at 11 mg / kg and for the neurotoxicity the NT 50 > 500 mg / kg.
• the aim of the investigations with compounds of the general formula 1 is to estimate the possible influence in models for examining the effect against anxiety states.
• the animals were exposed to different conflict situations and an influence, for example by the compound 1 - (4-chlorophenyl) -4-morpholin-4-yl-1, 5-dihydro-pyrrol-2-one (example 4), was measured.
• Avoidance reactions occur which can be suppressed by substances with an anxiolytic effect.
• the number of tolerated current surges of the animals treated with the substance compared to the vehicle-treated control group is assessed as a measure of the anxiolytic effect.
• Equieffective doses of diazepam and clonazepam are 1 to 3 mg / kg po.o. and 1 mg / kg p.o.
• mice are placed in an elevated gait system with open and closed arms (Pellow, S., Chopin, P., File SE, Briley, M .: Validation of open: closed arm entries in an elevated plus-maze as a measure of anxiety in rats. J. of Neuroscience Methods 14: 149-167, 1985; Hogg, S .: A review of the validity and variability of the elevated plus-maze as an animal model of anxiety. Pharmacology Biochemistry and Behavior: 21- 30, 1996). Untreated animals are increasingly striving towards the closed corridors. Anxiety inhibition is measured by the length of stay in the open arms as a percentage of the total length of stay. Treatments with the compounds of the general formula 1 increase the length of stay in the open arms as a percentage, as can be seen from Table 3.
• Formula 1 has a significantly wider therapeutic range.
• the therapeutic index for compound 4 is> 50.
• the therapeutic index of diazepam in bird conflict test 13 serves to further illustrate the invention without restricting it.

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Pharmacology & Pharmacy (AREA)
• Neurosurgery (AREA)
• Biomedical Technology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• Neurology (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Pain & Pain Management (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
• Plural Heterocyclic Compounds (AREA)
• Pyrrole Compounds (AREA)

Applications Claiming Priority (3)

Publications (1)

Family

ID=7922190

Family Applications (1)

Country Status (20)

Families Citing this family (1)

Family Cites Families (2)

• 1999
  • 1999-09-16 DE DE19944332A patent/DE19944332A1/de not_active Withdrawn
• 2000
  • 2000-08-30 CA CA002317257A patent/CA2317257A1/en not_active Abandoned
  • 2000-08-31 US US09/652,488 patent/US6500821B1/en not_active Expired - Fee Related
  • 2000-09-02 BR BR0013961-0A patent/BR0013961A/pt not_active Application Discontinuation
  • 2000-09-02 EP EP00960584A patent/EP1212297A1/de not_active Withdrawn
  • 2000-09-02 EE EEP200200137A patent/EE200200137A/xx unknown
  • 2000-09-02 HU HU0202607A patent/HUP0202607A3/hu unknown
  • 2000-09-02 JP JP2001523373A patent/JP2003509407A/ja active Pending
  • 2000-09-02 CN CN00812985A patent/CN1374948A/zh active Pending
  • 2000-09-02 SK SK378-2002A patent/SK3782002A3/sk unknown
  • 2000-09-02 AU AU72830/00A patent/AU7283000A/en not_active Abandoned
  • 2000-09-02 WO PCT/EP2000/008572 patent/WO2001019793A1/de not_active Application Discontinuation
  • 2000-09-02 KR KR1020027003491A patent/KR20020027657A/ko not_active Application Discontinuation
  • 2000-09-02 TR TR2002/00678T patent/TR200200678T2/xx unknown
  • 2000-09-02 MX MXPA02001370A patent/MXPA02001370A/es unknown
  • 2000-09-02 CZ CZ2002915A patent/CZ2002915A3/cs unknown
  • 2000-09-02 IL IL14780800A patent/IL147808A0/xx unknown
  • 2000-09-15 AR ARP000104877A patent/AR025700A1/es unknown
• 2002
  • 2002-02-26 BG BG06437A patent/BG106437A/bg unknown
  • 2002-03-07 NO NO20021143A patent/NO20021143L/no unknown

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events